Prestige Consumer Healthcare Inc. to Release Fiscal 2023 First Quarter Earnings Results

Rhea-AI Summary

Prestige Consumer Healthcare Inc. (NYSE:PBH) will release its fiscal 2023 Q1 earnings on August 4, 2022, before market opening. A conference call to discuss the results will follow at 8:30 a.m. ET, accessible via the company's website. Participants can join through phone by dialing U.S./Canada: 833-634-2598 or internationally: 412-902-4108. A replay will be available for a week post-call using conference ID 9498360. The company markets a wide range of consumer healthcare products across North America and internationally.

TARRYTOWN, N.Y., July 11, 2022 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2023 first quarter earnings release on Thursday, August 4, 2022 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET.

To participate in the live Internet webcast, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com.   To participate in the conference call via phone, listeners calling from the U.S. and Canada may dial 833-634-2598, or 412-902-4108 internationally, and reference joining the Prestige Consumer Healthcare earnings call.

A conference call replay will be available for approximately one week following completion of the live call and can be accessed on the Company’s Investor Relations page or at 877-344-7529 within the U.S., 855-669-9658 in Canada, and 412-317-0088 internationally using the conference ID is 9498360.

About Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare markets, sells, manufactures and distributes consumer healthcare products to retail outlets throughout the U.S. and Canada, Australia, and in certain other international markets. The Company’s diverse portfolio of brands include Monistat^® and Summer’s Eve^® women's health products, BC^® and Goody's^® pain relievers, Clear Eyes^® and TheraTears® eye care products, DenTek^® specialty oral care products, Dramamine^® motion sickness treatments, Fleet^® enemas and glycerin suppositories, Chloraseptic^® and Luden's^® sore throat treatments and drops, Compound W^® wart treatments, Little Remedies^® pediatric over-the-counter products, Boudreaux’s Butt Paste^® diaper rash ointments, Nix^® lice treatment, Debrox^® earwax remover, Gaviscon^® antacid in Canada, and Hydralyte^® rehydration products and the Fess^® line of nasal and sinus care products in Australia. Visit the Company's website at www.prestigeconsumerhealthcare.com.

Investor Relations Contact
Phil Terpolilli, CFA, 914-524-6819
irinquiries@prestigebrands.com

FAQ

When will Prestige Consumer Healthcare report its fiscal 2023 Q1 earnings?

Prestige Consumer Healthcare will report its fiscal 2023 Q1 earnings on August 4, 2022.

What time is the conference call for Prestige Consumer Healthcare's Q1 earnings?

The conference call will take place at 8:30 a.m. ET on August 4, 2022.

How can I access the conference call for Prestige Consumer Healthcare's earnings?

You can access the call via the company's website or by dialing 833-634-2598 in the U.S. and Canada, or 412-902-4108 internationally.

Is there a replay available for the Prestige Consumer Healthcare earnings call?

Yes, a replay of the earnings call will be available for one week following the live event.